Abstract
The effect of renal failure on melphalan pharmacology and toxicity has been poorly understood. Such information is of interest because melphalan is the most commonly used anticancer drug in the treatment of multiple myeloma, which is frequently associated with renal failure. We have studied the disposition and marrow toxicity of parenteral melphalan in dogs before and after induction of renal failure with subtotal nephrectomy. The surgical procedure decreased the creatinine clearance by an average of 62% (P = 0.001). The lowest neutrophil counts following i.v. melphalan (1 mg/kg) averaged 4.9 x 10(3)/mm3 pre-nephrectomy and 0.9 x 10(3)/mm3 post-nephrectomy, respectively (P = 0.002). The mean lowest recorded platelet counts after melphalan (1 mg/kg) were 115 x 10(3)/mm3 in the pre-nephrectomized dogs, and 9.7 x 10(3/mm3 in those who had been nephrectomized (P = 0.002). Following nephrectomy, i.v. melphalan's terminal-phase plasma half-life and renal clearance were both raised (P = 0.02) to 75% over pre-nephrectomy values. These studies show that i.v. melphalan-induced myelosuppression is markedly increased and its plasma elimination and renal clearance significantly decreased in the presence of renal dysfunction in dogs. These data suggest that parenteral melphalan's starting dose be decreased by at least 50% when used in myeloma patients with renal failure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Alberts, D., Chen, H., Benz, D. et al. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43, 330–334 (1981). https://doi.org/10.1038/bjc.1981.52
Issue Date:
DOI: https://doi.org/10.1038/bjc.1981.52
This article is cited by
-
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model
Bone Marrow Transplantation (2006)
-
Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure
Leukemia (2000)
-
Renal function in the elimination of oral melphalan in patients with multiple myeloma
Cancer Chemotherapy and Pharmacology (1986)
-
Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma
Cancer Chemotherapy and Pharmacology (1982)